137766-74-6

Basic information

• Product Name: (S)-2-Phenylpiperazine
• CAS NO: 137766-74-6
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.235
• Mol File: 137766-74-6.mol

Chemical Properties

• Boiling Point: 289.2 °C at 760 mmHg
• Flash Point: 169 °C
• Density: 0.997 g/cm³
• CAS DataBase Reference: (S)-2-Phenylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-Phenylpiperazine(137766-74-6)
• EPA Substance Registry System: (S)-2-Phenylpiperazine(137766-74-6)

Safety Data

• Hazardous Substances Data: 137766-74-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-Phenylpiperazine is used as a key building block for the synthesis of pharmaceutical compounds, specifically for the development of antipsychotics, antidepressants, and other psychiatric medications. Its role in these medications is attributed to its potent serotonin and norepinephrine reuptake inhibitory properties, which are crucial for managing mood disorders.
Used in Antidepressant Medications:
In the field of psychiatry, (S)-2-Phenylpiperazine is utilized as an active pharmaceutical ingredient in antidepressant formulations. It is valued for its ability to inhibit the reuptake of serotonin and norepinephrine, neurotransmitters that play a significant role in mood regulation, thereby helping to alleviate symptoms of depression and anxiety disorders.
Used in Neuroprotective and Anti-inflammatory Research:
(S)-2-Phenylpiperazine is also used in scientific research as a potential neuroprotective agent, with studies exploring its capacity to protect neurons from damage and degeneration. Additionally, it is being investigated for its anti-inflammatory properties, which could have implications for treating conditions with an inflammatory component.
However, due to its potential hazardous effects and toxicity, (S)-2-Phenylpiperazine must be handled and used with caution, ensuring that safety protocols are strictly adhered to in its application and synthesis processes.

Upstream product

• 15028-39-4 L-2-phenylglycine methyl ester hydrochloride 
• 134521-82-7 (R)-3-phenylpiperazine-2,5-dione 
• 2900-27-8 (2S)-2-[(tert-butoxycarbonyl)amino]-2-phenylethanoic acid 

Downstream Products

• 1042984-12-2 C₂₁H₂₁N₅O 

Relevant articles and documents

Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor

The invention provides a histone demethylase LSD1 (lysine specific demethylase 1) inhibitor. The invention relates to piperazine-containing compounds and pharmacologically acceptable salts thereof and use of the piperazine-containing compounds and pharmacologically acceptable salts thereof as the LSD1 inhibitor; the general structural formula of the piperazine-containing compounds is described in the description. The invention belongs to the field of pharmaceutical chemistry. An in-vitro LSD1 activity inhibition test proves that the piperazine-containing compounds implemented by the invention have an obvious inhibiting effect for LSD1 activity, thus being used as active ingredients for preparing LSD1 inhibitor medicines.

Asymmetric synthesis of 2-arylpiperazines

An asymmetric synthesis of 2-arylpiperazines starting from phenacyl bromides, a variety of which are easily available, has been established. The synthesis features a CBS reduction of phenacyl bromide to provide optically enriched compounds, an SN2 reaction of 1,2,3-oxathiazolidine 2-oxides with an azide anion with invert of configuration, and construction of the piperazine ring via reduction of piperazine-2,3-diones.

Small molecule disruptors of the Glucokinase-Glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept

Small molecule activators of glucokinase have shown robust efficacy in both preclinical models and humans. However, overactivation of glucokinase (GK) can cause excessive glucose turnover, leading to hypoglycemia. To circumvent this adverse side effect, we chose to modulate GK activity by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP). Disrupting the GK-GKRP complex results in an increase in the amount of unbound cytosolic GK without altering the inherent kinetics of the enzyme. Herein we report the identification of compounds that efficiently disrupt the GK-GKRP interaction via a previously unknown binding pocket. Using a structure-based approach, the potency of the initial hit was improved to provide 25 (AMG-1694). When dosed in ZDF rats, 25 showed both a robust pharmacodynamic effect as well as a statistically significant reduction in glucose. Additionally, hypoglycemia was not observed in either the hyperglycemic or normal rats.

Benzo[1,8]naphthyridine derivatives, their preparation and compositions containing them

New benzo[b][1,8]naphthyridine derivatives of general formula (I), in which R1 is a hydrogen atom or a hydroxyl or alkyl radical, R2 is a hydrogen atom or an alkyl, fluoroalkyl, cycloalkyl (3 to 6 C), alkyloxy or alkylamino radical, R3 is a phenyl or phenylalkyl radical substituted with one or more halogen atoms or alkyl, cycloalkyl (3 to 6 C), alkyloxy, cyano, amino, alkylamino, dialkylamino, alkyloxyalkyl, hydroxyalkyl, hydroxyalkyloxy, methylenedioxy, aminoalkyl, alkylaminoalkyl or dialkylaminoalkyl radicals, or R3 is a heterocyclic radical, and R4 is a hydrogen atom or a fluorine atom, the alkyl radicals (1 to 4 C) being linear or branched, their salts, their preparation and compositions containing them. These new products are useful as antimicrobials, or in the treatment of AIDS. STR1